Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma
Authors:
Open Access
- 26 November 2024
- journal article
- letter
- Published by Springer Nature in Biomarker Research
- Vol. 12 (1) , 1-6
Abstract
Circulating tumor DNA (ctDNA) has shown potential as a non-invasive tumor biomarker in neuroblastoma. Previous studies used generic assays for detection of selected predefined oncogenic variants as markers of ctDNA, which limits the sensitivity and excludes a subset of patients from analysis. Here we assessed patient-specific ctDNA analysis for treatment evaluation and detection of relapse in neuroblastoma. We generated personalized sequencing panels targeting 10 tumor-specific single nucleotide variants (SNVs) for each patient and performed ctDNA analysis of 136 plasma samples collected longitudinally in 13 children with neuroblastoma. ctDNA was detected using ultra-deep next generation sequencing with unique molecular identifiers to eliminate polymerase-induced errors. We found that the levels of ctDNA at diagnosis correlated with risk group and decreased gradually during effective treatment. All samples collected during follow-up in patients without disease relapse were ctDNA-negative. All four relapses were associated with elevated ctDNA levels, and a majority of the analyzed SNVs were detected at time of relapse. In one case, ctDNA became positive 78 days before the relapse was diagnosed with routine assessment and increased by over a thousandfold before the start of additional treatment. Overall, ctDNA was more uniformly elevated at diagnosis, showed less putative false positive results, and was more sensitive for detection of relapse compared to five serum or urine tumor markers used in clinical routine. In conclusion, personalized ctDNA analysis is suitable for clinical monitoring of tumor burden and may be used in all neuroblastoma patients regardless of risk group or tumor genetics.Keywords
Funding Information
- Wallenberg Centre for Molecular and Translational Medicine
- Barncancerfonden
- Svenska Sällskapet för Medicinsk Forskning
- Cancerfonden
- Vetenskapsrådet
- Sjöbergstiftelsen
- Sweden’s Innovation Agency
- Västra Götalandsregionen
- Lion’s Cancer Research Fund of Western Sweden
- The Swedish state under the agreement between the Swedish government and the county councils, the ALF‐agreement
- the Assar Gabrielsson Foundation
- The Swedish Society of Medicine
- Sahlgrenska International Starting Grant
- Svensson’s research fund
This publication has 13 references indexed in Scilit:
- Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk NeuroblastomaCancer Discovery, 2022
- Postchemotherapy gross residual tumor in non‐high‐risk neuroblastoma: Clinical significance and the role of adjuvant therapyPediatric Blood & Cancer, 2022
- Advancing therapy for neuroblastomaNature Reviews Clinical Oncology, 2022
- Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with NeuroblastomaClinical Cancer Research, 2022
- Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and ALK Genotyping via Cell-Free Circulating Tumor DNA ProfilingCancers, 2021
- Nuclear Medicine Imaging in Neuroblastoma: Current Status and New DevelopmentsJournal of Personalized Medicine, 2021
- A Targeted Gene Panel for Circulating Tumor DNA Sequencing in NeuroblastomaFrontiers in Oncology, 2020
- Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencingNature Protocols, 2017
- Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosisJapanese Journal of Clinical Oncology, 2016
- Detection of tumor ALK status in neuroblastoma patients using peripheral bloodCancer Medicine, 2015